Hemispherx’s Ampligen Needs Another Study, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis Advisory Committee recommends against approval of rintatolimod for chronic fatigue syndrome, saying that signs of efficacy seen in post-hoc analyses warrant further, prospective exploration in a new study before approval.
You may also be interested in...
FDA Takes Dim View Of Ampligen For Chronic Fatigue Syndrome
In review documents released ahead of a Dec. 20 advisory committee meeting, agency questions the validity of Hemispherx’s post-hoc efficacy analyses and raises concerns about adverse events and the reliability of the safety data.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.